What are the recommended pharmacologic treatments and dosing for tics?

Pharmacologic Treatment for Tics

For moderate to severe tics requiring medication, start with risperidone (0.01 mg/kg/day, titrated weekly up to 0.06 mg/kg/day) or tiapride as first-line agents, reserving alpha-2 agonists like clonidine (starting 0.05 mg at bedtime, titrated to 0.3-0.4 mg/day divided) for milder cases or when antipsychotic side effects are a concern 1, 2.

Treatment Algorithm

Step 1: Determine if Medication is Needed

• Only treat when tics cause functional impairment in school, work, or daily activities 3, 4
• Many tics are mild and require only education and reassurance 3
• Critical pitfall: Comorbid ADHD, OCD, anxiety, or depression occur in >50% of patients and may be more disabling than the tics themselves—address the most troubling symptom first 3, 1

Step 2: First-Line Pharmacotherapy

For Mild to Moderate Tics:

• Clonidine: Start 0.05 mg at bedtime, increase by 0.05 mg every 4-7 days to maximum 0.3-0.4 mg/day divided 3-4 times daily 3
• Guanfacine: Start 0.5 mg at bedtime, increase by 0.5 mg weekly to maximum 3-4 mg/day divided twice daily 3
• These alpha-2 agonists have the best safety profile and received strong recommendations in Canadian guidelines 2

For Moderate to Severe Tics:

• Risperidone (preferred atypical antipsychotic): Start 0.01 mg/kg/day once daily, increase by 0.02 mg/kg/day weekly up to 0.06 mg/kg/day 3, 1
  • Best evidence level among atypical antipsychotics 1
  • Additional benefit for behavioral problems 3
• Tiapride (European preference): Largest clinical experience in Europe with low adverse reaction rates 1

Step 3: Second-Line Options

Aripiprazole: Limited but promising data with lower risk of metabolic side effects compared to other antipsychotics 1, 5

Pimozide: Best evidence among typical antipsychotics but higher side effect burden 1, 2

Other atypicals: Ziprasidone and olanzapine are reasonable alternatives 3

Step 4: Severe, Refractory Cases

For patients failing at least three medications (including anti-dopaminergics and alpha-2 agonists) plus behavioral therapy 6:

• Tetrabenazine (VMAT2 inhibitor) 2, 5
• Topiramate 2, 5
• Botulinum toxin injections for focal, disabling motor tics 2
• Deep brain stimulation only for patients >20 years old with severe, treatment-refractory tics causing major functional impairment 6

Special Populations and Comorbidities

Tics + ADHD:

• Use atomoxetine, stimulants, or clonidine first 1
• If tics are severe, combine stimulants with risperidone 1

Tics + OCD/Anxiety/Depression:

• Mild-moderate tics: Sulpiride monotherapy 1
• Severe cases: Risperidone + SSRI combination 1

Critical Evidence Considerations

The 2022 European guidelines 7 and 2013 pharmacology review 1 represent the most comprehensive recent guidance. Notably, there's been a significant shift toward non-pharmacological treatments over the past decade 7, but when medication is needed, the evidence hierarchy is clear:

• Strongest evidence: Dopamine D2 receptor blockers (efficacy proportionate to D2 affinity) 3
• Best tolerability: Alpha-2 agonists for mild-moderate cases 2
• Practical compromise: Atypical antipsychotics before typical neuroleptics due to better side effect profiles, despite typical agents having slightly stronger efficacy 3, 1

Important Caveats

• All antipsychotics received only weak recommendations in Canadian guidelines due to high side effect rates, despite proven efficacy 2
• Natural history favors spontaneous improvement—nearly 50% of patients improve by age 18 6
• Treatment decisions must weigh tic suppression benefits against medication risks, particularly metabolic and extrapyramidal side effects with antipsychotics 2, 5
• Age consideration: Avoid surgical interventions before age 20 due to high spontaneous remission rates 6